

**Percorso di Formazione A Distanza:
" e-Micro Learning "**

FAD e-Learning: N° ECM: 106 – 322703

SEDE PIATTAFORMA FAD: UFFICI PKG srl: Firenze, via Giovanni del Pian dei Carpinì 96/7 – 50127
INDIRIZZO PIATTAFORMA WEB: www.pkg-education.com
INDIRIZZO SERVER: www.pkg-education.com

INFORMAZIONI DI DETTAGLIO SUL PROGRAMMA FORMATIVO

RAZIONALE

La Microbiologia clinica è una disciplina finalizzata allo studio, alla diagnosi ed alla terapia delle malattie dell'uomo causate direttamente o indirettamente da microorganismi. Il fine ultimo di questa attività è quello di garantire ai clinici gli strumenti necessari per eseguire una diagnosi sicura in tempi rapidi, attuare una terapia mirata e, eventualmente, pianificare e mettere in atto una serie di procedure atte ad impedire il diffondersi delle infezioni.

Il microbiologo ha anche una importante responsabilità nella interpretazione dei dati microbiologici, che dipende da diversi fattori quali ad esempio la qualità del campione, la valutazione del microorganismo isolato come patogeno primario o opportunisto, il sospetto clinico o l'ipotesi diagnostica, le condizioni immunitarie del soggetto al momento del prelievo.

Il corso e-micro learning intende affrontare alcune tematiche attuali della microbiologia clinica con una modalità di formazione interattiva teorico-pratica, allo scopo di migliorare le competenze dei microbiologi e per aprire un confronto costruttivo sulla possibile risoluzione di problemi aperti che non trovano al momento una linea guida di indirizzo scientificamente validata.



PKG
EDUCATIONAL PACKAGES

PKG s.r.l.
Via G. del Pian dei Carpinì 96/7 - 50127 Firenze
Tel. 055.411625 - Fax 0554224290
Capitale Sociale Euro 10.000 I.V.
Cod. Fiscale P IVA e Registro Imprese Firenze 05582670484

OBIETTIVI FORMATIVI E COERENZA CON L'OBBIETTIVO NAZIONALE

Coerenza con Obiettivo Nazionale N° 2: Linee guida – Protocolli – Procedure

DESTINATARI

Il percorso formativo è rivolto a Medici Chirurghi con specializzazione in:

- Biomichimica clinica
- Microbiologia e Virologia

Ed a:

- Biologo
- Chimico
- Tecnico sanitario di laboratorio biomedico

DURATA DEL CORSO

La FAD e-learning sarà attiva dal **31 MAGGIO** al **20 GIUGNO 2021**.

ATTIVITA' DI TUTORAGGIO E MODALITÀ DI EROGAZIONE DEL PERCORSO FORMATIVO

Non è prevista attività di tutoraggio.



PROGRAMMA

FAD E-LEARNING

1° STEP PERCORSO FAD e-learning (durata 3 ore) attiva dal 31 MAGGIO al 10 GIUGNO 2021

| RELAZIONE | RELATORE |
|---|-------------------------|
| Introduzione alla FAD e presentazione degli obiettivi formativi | E. Carretto L. Drago |
| Lezione interattiva: Sierologia COVID | E. Carretto |
| Lezione interattiva: Le Polmoniti Batteriche | L. Drago |
| Conclusioni e take home messages | E. Carretto L. Drago |

2° STEP PERCORSO FAD WEB Conference (durata 2,5 ore) 14 GIUGNO 2021

| ORARIO | RELAZIONE | RELATORE |
|---|--|-------------------------|
| 14.55 – 15.00 | Introduzione e presentazione degli obiettivi del corso | E. Carretto L. Drago |
| RECAP TEMI TRATTATI DURANTE LA FASE E-LEARNING | | |
| 15.00 – 16.15 | Sierologia COVID Analisi dati emersi dalle lezioni interattive Questions & Answers | E. Carretto |
| 16.15 – 17.30 | Le Polmoniti Batteriche Analisi dati emersi dalle lezioni interattive Questions & Answers | L. Drago |

Durata complessiva 5 ore.

RESPONSABILE SCIENTIFICO

Responsabili Scientifici: Dott. Edoardo CARRETTO, Prof. Lorenzo DRAGO



PKG s.r.l.
Via G. del Pian dei Carpini 96/7 - 50127 Firenze
Tel. 055.411625 - Fax 0554224290
Capitale Sociale Euro 10.000 I.V.
Cod. Fiscale P IVA e Registro Imprese Firenze 05582670484

NUMERO CREDITI ECM ASSEGNATI

All'evento sono stati assegnati 5 crediti ECM

FACULTY (in ordine alfabetico)

| | | | |
|----------|---------|-------------------------------------|---|
| CARRETTO | EDOARDO | RELATORE E RESPONSABILE SCIENTIFICO | LAUREA: Medicina e Chirurgia SPECIALIZZAZIONE: Malattie Infettive, Microbiologia e Virologia AFFILIAZIONE: Direttore S.C. di Microbiologia, IRCCS Arcispedale Santa Maria Nuova – REGGIO EMILIA |
| DRAGO | LORENZO | RELATORE E RESPONSABILE SCIENTIFICO | LAUREA: Scienze Biomediche SPECIALIZZAZIONE: Microbiologia Clinica e Virologia AFFILIAZIONE: Professore Associato di Microbiologia Clinica presso l'Università degli Studi di Milano e Responsabile del Laboratorio di Microbiologia Clinica e della piattaforma di metagenomica microbica per lo studio del Microbiota umano presso il Dipartimento di Scienze Biomediche per la Salute della Facoltà di Medicina e Chirurgia di Milano - MILANO |

VALUTAZIONE DELL'APPRENDIMENTO

Al termine dell'intero percorso i partecipanti dovranno compilare un questionario di apprendimento finale ai fini dell'erogazione dei crediti ECM.

DATI PROVIDER

Accreditamento Provider: PKG srl con decorrenza dal 15/10/2012 è Provider Standard Nazionale con numero identificativo 106 dopo aver ottenuto il parere positivo dalla Commissione Nazionale per la Formazione Continua. Tale accreditamento è valido per un periodo di 4 anni ai sensi dell'Accordo stipulato in sede di Conferenza permanente per i rapporti tra lo Stato, le Regioni e le Province Autonome di Trento e Bolzano in data 5 novembre 2009 e del suo Regolamento Applicativo approvato dalla Commissione Nazionale per la Formazione Continua in data 13/01/2010 e successive modifiche del 19 aprile 2012. PKG s.r.l. è inoltre certificata UNI EN ISO 9001:2015 per la progettazione ed erogazione di servizi di formazione continua in medicina come provider ECM (Certificato TUV 50 100 9892).



PKG
EDUCATIONAL PACKAGES

PKG s.r.l.
Via G. del Pian dei Carpini 96/7 - 50127 Firenze
Tel. 055.411625 - Fax 0554224290
Capitale Sociale Euro 10.000 I.V.
Cod. Fiscale P IVA e Registro Imprese Firenze 05582670484

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**

INFORMAZIONI PERSONALI

Nome Edoardo Carretto
Indirizzo [REDACTED]
Telefono [REDACTED]
Fax [REDACTED]
E-mail [REDACTED]
Nazionalità [REDACTED]
Data e luogo di nascita [REDACTED]
Codice fiscale [REDACTED]

ESPERIENZA LAVORATIVA

- Date (da - a)
 - 10 gennaio 2011 a tutt'oggi. Direttore S.C. di Microbiologia, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia
 - 20 settembre 1998 - 09 gennaio 2011. Dirigente Medico presso la S.C. Virologia e Microbiologia, Laboratori Sperimentali di Ricerca Area Infettivologica, Fondazione IRCCS Policlinico "San Matteo", Pavia
 - 30 dicembre 1994 - 20 agosto 1996. Assistente Medico, Reparto Malattie Infettive, Ospedale di Piacenza (PC) Istituto di Ricovero e Cura a Carattere Scientifico Arcispedale Santa Maria Nuova, Viale Risorgimento, 80 - 42123 Reggio Emilia Ospedale pubblico
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego
- Principali mansioni e responsabilità
 - Direttore di Struttura Complessa
 - Direttore della S.C. di Microbiologia. Settori di lavoro: diagnostica e ricerca applicata.

ISTRUZIONE E FORMAZIONE

- Date (da - a)
 - 1999-2002. Specializzazione in Microbiologia e Virologia, Università di Torino
 - 1989-1993. Specializzazione in Malattie Infettive, Università di Pavia
 - 1982-1989. Laurea in Medicina e Chirurgia, Università di Pavia
- Nome e tipo di istituto di istruzione o formazione
 - vedi sopra
 - vedi sopra
 - vedi sopra
 - vedi sopra
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita
- Livello nella classificazione nazionale (se pertinente)

CAPACITÀ E COMPETENZE

PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

MADRELINGUA

italiano

ALTRE LINGUA

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

inglese, tedesco, francese

inglese, ottima; tedesco, buona; francese, buona

inglese, buona; tedesco, buona; francese, elementare

inglese, buona; tedesco, elementare; francese, elementare

CAPACITÀ E COMPETENZE

RELAZIONALI

Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.

[Descrivere tali competenze e indicare dove sono state acquisite.]

CAPACITÀ E COMPETENZE

ORGANIZZATIVE

Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.

Per quanto attiene l'ambito della microbiologia clinica, coordina e dirige progetti di ricerca nell'ambito del proprio Ospedale; ha promosso e coordinato studi multicentrici nazionali; ha fatto parte di indagini multicentriche internazionali, coordinando gruppi di ricerca anche a carattere internazionale. Principali settori di interesse: tipizzazione microbica con tecniche molecolari in outbreak ospedalieri; identificazione e caratterizzazione di geni di resistenza; tipizzazione e identificazione di stafilococchi coagulasi negativi; procedure di sorveglianza e controllo delle infezioni da germi multiresistenti; sorveglianza e controllo delle infezioni correlate all'assistenza.

CAPACITÀ E COMPETENZE

TECNICHE

Con computer, attrezzature specifiche, macchinari, ecc.

Buone conoscenze e discreta esperienza pratica di apparecchiature biotecnologiche (termociclatori, apparecchiature per analisi molecolari di isolati batterici quali sequenziatori, PFGE, ribotipizzatore automatico, ecc). Ottime conoscenze informatiche sui principali pacchetti applicativi, in ambito di gestionali di laboratorio e di softwares per analisi e interpretazione dei dati di biologia molecolare.

CAPACITÀ E COMPETENZE

ARTISTICHE

Musica, scrittura, disegno ecc.

[Descrivere tali competenze e indicare dove sono state acquisite.]

ALTRE CAPACITÀ E COMPETENZE

Competenze non precedentemente indicate.

- Dal 2003 è membro dell'APSI (Associazione per la Prevenzione e lo Studio delle Infezioni), di cui è stato Consigliere dal 2003 al 2008. Dal gennaio 2009 a tutt'oggi ricopre la carica di Segretario dell'Associazione. In tale ambito coordina l'attività dell'organizzazione, organizzando convegni e congressi.
- Dal 2007 è membro della SIMPIOS (Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle

Organizzazioni Sanitarie); di tale società è stato chiamato a far parte del comitato scientifico a partire dal 2010 al 2013. Dal giugno 2014 a maggio 2018 ha fatto parte del Consiglio Direttivo. Dal maggio 2016 a maggio 2018 è stato tesoriere dell'associazione. - Relatore a congressi nazionali e internazionali (oltre 50 relazioni negli ultimi 5 anni)

PATENTE O PATENTI

automobilistica

ULTERIORI INFORMAZIONI

Autore di numerose pubblicazioni scientifiche in ambito clinico e microbiologico (più di 60 delle quali su riviste con IF) e di oltre dieci capitoli di libri. Reviewer di riviste scientifiche quali Journal of Clinical Microbiology, Clinical Microbiology and Infection, Research in Microbiology, European Journal of Clinical Microbiology and Infectious Diseases, Microbial Drug Resistance.

Analisi della produttività scientifica al 01 gennaio 2020, valutata attraverso il software "Publish or Perish" (Harzing A.W. - Publish or Perish (2007, <https://harzing.com/resources/publish-or-perish>, versione 7.15.2643.7260):

1276 citazioni complessive per 94 pubblicazioni. Hirsch's index = 21; Egghe's index = 34; contemporary Hirsch's index = 18; individual Hirsch's index = 4,69; individual Hirsch's index normalizzato = 10; media normalizzata annuale aumento Hirsch's index = 0,36; age-weighted citation rate = 160,68; Zhang's index = 23,00.

L'analisi utilizzando Scopus (Author ID: 56063758900) documenta un Hirsch's index di 17, con 833 citazioni per 64 pubblicazioni.

ALLEGATI

=

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali ai sensi del Regolamento UE 2016/679 sul trattamento dei dati personali e del precedente D.Lgs. 196/03.

Pavia, martedì 1 dicembre 2020



CURRICULUM VITAE

First Name: Lorenzo
Last Name: Drago
Date and Place of Birth: 16/10/1962, Aidone (EN), Italia
Address:
Language / Citizenship: Italian and English / Italian

Education

Sept 1997: Ph.D. in Clinical Microbiology at the University of Milan. Thesis: “Uropathogen *Escherichia coli*: adhesions and cellular receptors”.

Nov 1992: Specialization degree in Clinical Microbiology and Virology at the University of Catane, 50/50 cum laude. Thesis: “Ecological impact of ceftibuten on intestinal microflora”.

July 1990: Exam eligibility status for authorization to practice.

Nov 1988: High degree in Biomedical Sciences at the University of Catane, 110/110. Thesis: “Incidence of *Actinomyces israeliti* on women with IUD”.

1982: High School diploma.

Positions

November 2016 to now Associate Professor of Clinical Microbiology at University of Milan -Faculty of Medicine and Surgery – Dept of Biomedical Sciences for Health – Milan. Working Area Microbiology and Clinical Microbiology (MED 07).

October 2008 to 2018: Chief of the Clinical-Chemistry and Microbiological Lab, IRCCS Galeazzi Hospital, Milan.

Jan 2006 to 2008 Director of the “High Emergency Microorganisms” Lab (BSL4 Lab) at L.Sacco Teaching Hospital – University of Milan.

Apr 2005 to 2008: Head of of the “High Emergency Microorganisms” Lab (BSL4 Lab) at L.Sacco Teaching Hospital – University of Milan.

Oct 2002: Care functions at L.Sacco Teaching Hospital – Laboratory of Clinical Microbiology

Oct 2002 to 2016 Researcher and Adjunt Professor at the University of Milan – Faculty of Medicine and Surgery – Dept of Preclinical Science DISP LITA – Milan. Working Area Microbiology and Clinical Microbiology (MED 07).

1996-2002: Leading position of 1st level in the Microbiology Lab at L.Sacco Teaching Hospital – Milan

Teaching

- 1992-1996:** Tutor for the course of *Microbiology and Clinical Microbiology*- Laboratory Technician – University of Milan.
- 1992-2001:** Tutor at the Department of *General Microbiology and Clinical Microbiology* – Faculty of Medicine and Surgery – University Campus LITA (Sacco Hospital), University of Milan.
- 1996-2001:** Tutor for postgraduates students of Specialization School in Microbiology and Virology – University of Milan.
- 2001-2002:** No charge-contract as teacher for *Clinical Microbiology Course* in Integrated course of General Diagnostic line A – Faculty of Medicine and Surgery, University of Milan.
- 2002-2004:** Professor of *Microbiology and Clinical Microbiology* – CDL Degree in Medicine and Surgery – University of Milan (Niguarda Hospital, Legnano Hospital, San Carlo Hospital).
- 2003-2005:** Professor of *Clinical Diagnostics* – CDL Nursing, Faculty of Medicine and Surgery – University of Milan (Niguarda Hospital, Sacco Hospital, San Carlo Hospital).
- 2004-2005:** Professor of *Diagnostics of infectious diseases, Bacteriological and mycological techniques, Medical bacteriology* – School of Specialization in Tropical Medicine, Faculty of Medicine and Surgery, University of Milan.
- 2005-2006:** Professor of *Clinical Diagnostics* – CDL Nursing, Faculty of Medicine and Surgery – University of Milan (Niguarda Hospital, Sacco Hospital, San Carlo Hospital).
- 2005-2006:** Professor of *Diagnostics of infectious diseases, Bacteriological and mycological techniques, Medical bacteriology* – School of Specialization in Tropical Medicine, Faculty of Medicine and Surgery, University of Milan.
- 2006-2007:** Professor of *Clinical Diagnostics* – CDL Nursing, Faculty of Medicine and Surgery – University of Milan (Niguarda Hospital, Sacco Hospital, San Carlo Hospital).
- 2006-2007:** Professor of *Diagnostics of infectious diseases, Bacteriological and mycological techniques, Medical bacteriology* – School of Specialization in Tropical Medicine, Faculty of Medicine and Surgery, University of Milan.
- 2006-2007:** Professor of *Diagnostics of infectious diseases* – School of Specialization in Infectious Diseases, Faculty of Medicine and Surgery, University of Milan.
- 2007-2008:** Professor of *Clinical Diagnostics* – CDL Nursing, Faculty of Medicine and Surgery – University of Milan (Niguarda Hospital, Sacco Hospital, San Carlo Hospital).
- 2007-2008:** Professor of *Diagnostics of infectious diseases, Bacteriological and mycological techniques, Medical bacteriology* – School of Specialization in Tropical Medicine, Faculty of Medicine and Surgery, University of Milan.
- 2007-2008:** Professor of *Diagnostics of infectious diseases* – School of Specialization in Infectious Diseases, Faculty of Medicine and Surgery, University of Milan.
- 2008-2009:** Professor of *Clinical Diagnostics* – CDL Nursing, Faculty of Medicine and Surgery – University of Milan (Niguarda Hospital, Sacco Hospital, San Carlo Hospital).
- 2008-2009:** Professor of *Diagnostics of infectious diseases, Bacteriological and mycological techniques, Medical bacteriology* – School of Specialization in Tropical Medicine, Faculty of Medicine and Surgery, University of Milan.
- 2008-2009:** Professor of *Diagnostics of infectious diseases* – School of Specialization in Infectious Diseases, Faculty of Medicine and Surgery, University of Milan.
- 2009-2010:** Professor of *Clinical Diagnostics* – CDL Nursing, Faculty of Medicine and Surgery – University of Milan (Garbagnate Hospital, Sacco Hospital, San Carlo Hospital).
- 2009-2010:** Professor of *Clinical diagnostics* – CDL Podiatry, Faculty of Medicine and Surgery, University of Milan (Galeazzi Hospital).
- 2009-2010:** Professor of *Diagnostics of infectious diseases, Bacteriological and mycological techniques, Medical bacteriology* – School of Specialization in Tropical Medicine, Faculty of Medicine and Surgery, University of Milan.
- 2009-2010:** Professor of *Diagnostics of infectious diseases* – School of Specialization in Infectious Diseases, Faculty of Medicine and Surgery, University of Milan.
- 2010-2011:** Professor of *Clinical Diagnostics* – CDL Nursing, Faculty of Medicine and Surgery – University of Milan (Sacco Hospital, San Carlo Hospital).
- 2010-2011:** Professor of *Clinical diagnostics* – CDL Podiatry, Faculty of Medicine and Surgery, University of Milan (Galeazzi Hospital).

- 2010-2011:** Professor of *Diagnostics of infectious diseases, Bacteriological and mycological techniques, Medical bacteriology* – School of Specialization in Tropical Medicine, Faculty of Medicine and Surgery, University of Milan.
- 2010-2011:** Professor of *Diagnostics of infectious diseases* – School of Specialization in Infectious Diseases, Faculty of Medicine and Surgery, University of Milan.
- 2011-2012:** Professor of *Clinical Diagnostics* – CDL Nursing, Faculty of Medicine and Surgery – University of Milan (Garbagnate Hospital, Sacco Hospital, San Carlo Hospital).
- 2011-2012:** Professor of *Clinical diagnostics* – CDL Podiatry, Faculty of Medicine and Surgery, University of Milan (Galeazzi Hospital).
- 2011-2012:** Professor of *Clinical Microbiology diagnostics Lab* – CDL Lab Biomedical Technicians, Faculty of Medicine and Surgery, University of Milan..
- 2012-2013:** Professor of *Clinical Diagnostics* – CDL Nursing, Faculty of Medicine and Surgery – University of Milan (Sacco Hospital,).
- 2012-2013:** Professor of *Clinical diagnostics* – CDL Podiatry, Faculty of Medicine and Surgery, University of Milan (Galeazzi Hospital).
- 2012-2013:** Professor of *Research and development of new diagnostic and therapeutic methodologies* – CDL Medical Biotechnology and Molecular Medicine, Faculty of Medicine and Surgery, University of Milan..
- 2013-2014:** Professor of *Clinical diagnostics* – CDL Podiatry, Faculty of Medicine and Surgery, University of Milan (Galeazzi Hospital).
- 2013-2014:** Professor of *Clinical Microbiology diagnostics Lab* – CDL Lab Biomedical Technicians, Faculty of Medicine and Surgery, University of Milan..
- 2013-2014:** Professor of *Research and development of new diagnostic and therapeutic methodologies* – CDL Medical Biotechnology and Molecular Medicine, Faculty of Medicine and Surgery, University of Milan..
- 2014-2015:** Professor of *Clinical diagnostics* – CDL Podiatry, Faculty of Medicine and Surgery, University of Milan (Galeazzi Hospital).
- 2014-2015:** Professor of *Clinical Microbiology diagnostics Lab* – CDL Lab Biomedical Technicians, Faculty of Medicine and Surgery, University of Milan..
- 2014-2015:** Professor of *Research and development of new diagnostic and therapeutic methodologies* – CDL Medical Biotechnology and Molecular Medicine, Faculty of Medicine and Surgery, University of Milan..
- 2016-2017:** Professor of *Research and development of new diagnostic and therapeutic methodologies* – CDL Medical Biotechnology and Molecular Medicine, Faculty of Medicine and Surgery, University of Milan..
- 2016-2017:** Professor of *Clinical diagnostics* – CDL Podiatry, Faculty of Medicine and Surgery, University of Milan (Galeazzi Hospital).
- 2016-2017:** Professor of *Clinical Microbiology diagnostics Lab* – CDL Lab Biomedical Technicians, Faculty of Medicine and Surgery, University of Milan..
- 2016-2017:** Professor of *Research and development of new diagnostic and therapeutic methodologies* – CDL Medical Biotechnology and Molecular Medicine, Faculty of Medicine and Surgery, University of Milan.
- 2017-2018:** Professor of *Research and development of new diagnostic and therapeutic methodologies* – CDL Medical Biotechnology and Molecular Medicine, Faculty of Medicine and Surgery, University of Milan..
- 2017-2018:** Professor of *Clinical diagnostics* – CDL Podiatry, Faculty of Medicine and Surgery, University of Milan (Galeazzi Hospital).
- 2017-2018:** Professor of *Clinical Microbiology diagnostics Lab* – CDL Lab Biomedical Technicians, Faculty of Medicine and Surgery, University of Milan..
- 2017-2018:** Professor of *Research and development of new diagnostic and therapeutic methodologies* – CDL Medical Biotechnology and Molecular Medicine, Faculty of Medicine and Surgery, University of Milan..

Member of Doctorate School in Medical Odontoiatry, Università degli Studi di Milano.

Scientific society member

Active member of National (SIM, AMCLI, GISTIO) and International Scientific Societies (ESCMID, ASM, ESIDOG, BEG group, EJIBS).

Member of Scientific Board of GISTIO (Gruppo di Studio delle Infezioni Osteoarticolari).

Member of CoSias group (AMCLI) for bone, joint and prosthetic infections.

Country Delegate for the European of Bone and Joints Infections Society (EBJIS).

Past Board Member of European of Bone and Joints Infections Society (EBJIS)

Directive Council Member of AMCLI and Responsible GLAM Microbiota group of AMCLI

Past President of the International Society of Microbiota – Pasteur Institute - Paris

Coordinator of WAIOT Scientific Committee

Activities as relator, referee and participation to Editorial Board

- Relator in numerous national and international courses and congresses.
- Referee in *Farmaci e Terapia*, *Journal of Chemotherapy*, *Journal of Antimicrobial Agents*, *Medical Science Monitor*, *BMC Microbiology*, *Antimicrobial Agents and Chemotherapy*, *Plos one*, *Clinical Microbiology and Infections*, *BMC Infect Diseases*.
- Member of Editorial Board (*International Journal of Probiotics and Prebiotics*).
- Member of Scientific Board and co-creator of the following site: www.ecosistemavaginale.it
- Member of Psoriasis Scientific Board.

Scientific projects funded

- FIRST (ex 60%) 2003
- FIRST (ex 60%) 2004
- FIRST (ex 60%) 2005
- FIRST (ex 60%) 2006
- PUR 2007
- PUR 2008
- PUR 2009
- Bando Metadistretti Regione Lombardia 2009: ATP 2009 “ID 13587782 AMICROTEX – *Effect of novel antimicrobial textiles for hospital setting*”
- FP7 - VII° EU Program – I.D.A.C. IDAC - *Implant Disposable Antibacterial Coating: a Novel Approach to Implant-Related Infections in Orthopaedics and Trauma Surgery*.
- Italian Ministry of University -PRIN 2010 - entitled “New insights into the mechanisms of inflammatory bowel disease and identification of new therapeutic targets.
- Cariplo Foundation 2012: *Development of an innovative user-friendly colorimetric biosensor based on aptamerfunctionalized nanomaterials for the detection of Staphylococcus aureus from different biological sources*.

Publications with Impact Factor

1. M.R. Gismondo, **L. Drago**, C. Fassina, M.L. Garlaschi, M. Rosina, A. Lombardi: *Escherichia coli*: effect of Fosfomycin Trometamol on some urovirulence factors. *J Chemother*, Vol. 6 (167-172), 1994. **Impact Factor: 1.33**
2. Gismondo M.R., **Drago L.**, Lombardi A., Fassina C.: Impact of Cefetamet-pivoxil on intestinal microflora: *in vivo* study. *J Chemother*, Vol. 6 (246-250), 1994. **Impact Factor: 1.33**
3. Gismondo M.R., Drago L., Lombardi A., Fassina C.: An experimental model to reproduce some bacterial intestinal cocultures in germ-free mice. *Drugs Exp. Clin. Res.*, Vol XX(4), 1994. **Impact factor: 1.030**
4. Gismondo M.R., Drago L., Lombardi A., Fassina C.: Impact of Ceftibuten on intestinal microflora: *in vitro* and *in vivo* studies. *Drugs Expt. Clin. Res.*, Vol XX(2), 1994. **Impact factor: 1.030**
5. Gismondo M.R., **Drago L.**, Lombardi A., Fassina C., Cesana M.: Impact of Rufloxacin and Ciprofloxacin on the intestinal microflora in a germ-free mice model. *Chemotherapy*, Vol. 41 (281-288), 1995. **Impact Factor: 0.992**
6. Gismondo MR, **Drago L.**, Lombardi A, Fassina MC, Mombelli B: Efficacia antimicrobica e sporicida di varie soluzioni disinfettanti. *Minerva Med*, Vol. 86 (21-32), 1995. **Impact factor: 1.236**
7. Calvani F., Macchia M., Rossello A., M.R. Gismondo, **Drago L.**, Fassina M.C., Cisternino M., Domiano P.: Synthesis and antiviral activity of dihydroxycyclohexyl Pyrimidine and Purine carbocyclic nucleosides. *Bioorganic & Medicinal Chemistry Letters*, Vol. 5, N. 21, 1995. **Impact Factor: 2.486**
8. **Drago L.**, Gismondo M.R., Lombardi A., De Haen C., Gozzini L.: Inhibition of *in vitro* growth of enteropathogens by new lactobacillus strains of human intestinal origin. *FEMS Microbiol Lett*, 153:455-463, 1997. **Impact Factor: 1, 858**
9. Atzori C., Agostoni F., Angeli E., Cargnel A., **Drago L.**, Gismondo M.R.: Algorithmic analysis of *in vitro* chemotherapy against *Pneumocystis carinii*. *J Eukaryot Microbiol*, 44(6):30S, 1997. **Impact Factor: 2.738**
10. Gismondo M.R., **Drago L.**, Lombardi A., Fassina M.C., Mombelli B.: Interference on *Helicobacter pylori* growth and adhesion by omeprazole and other drugs. *J Chemother*. 10 (3): 225-230, 1998. **Impact Factor: 1.33**
11. Gismondo M.R., **Drago L.**, Fassina M.C., Abbiati R., Grossi E.: Immunostimulating effect of oral glutamine. *Dig Dis Sci*. 43 (8): 1752-1754, 1998. **Impact Factor: 2.516**
12. Nardi G., **Drago L.**, De Vecchi E., Rosina M., Gismondo M.R.: Gastrointestinal and respiratory *Mycobacterium avium* colonisation and development of disseminated infection in HIV-positive patients. *Clin Microbiol Inf*, 5:176-177, 1999. **Impact Factor: 4.575**
13. **Drago L.**, Mombelli B., Ciardo G., De Vecchi E., Gismondo M.R.: Effects of three different fish oil formulations on *Helicobacter pylori* growth and viability: *In vitro* study. *J Chemother*, 11(3):179-182, 1999. **Impact Factor: 1.33**
14. **Drago L.**, Mombelli B., Fassina M.C., De Vecchi E., Gismondo M.R.: Evaluation of antibacterial activity of cefodizime, ceftriaxone and cefonicid in *Klebsiella pneumoniae*-infected guinea pigs. *Clin Microbiol Infect*, vol. 5 (6): 371-373, 1999. **Impact Factor: 4.575**
15. Gismondo M.R., **Drago L.**, Lombardi A.: Review of probiotics available to modify gastrointestinal flora. *Int J Antimicrob Agents*, 12: 287-292, 1999. **Impact Factor: 4.097**
16. **Drago L.**, Fassina MC, De Vecchi E, Mombelli B, Lombardi A, Gismondo MR. Lack of *in vitro* and *in vivo* selection of bacterial resistance by roxithromycin. *Chemotherapy* 2000, 46:160-5. **Impact Factor: 0.992**
17. **Drago L.**, De Vecchi E, Fassina MC, Mombelli B, Gismondo MR. Serum and lung levels of thiamphenicol after administration of its glycinate N-acetylcysteinate ester in experimentally infected guinea pigs. *Int J Antimicrob Agents* 2000, 13:301-3. **Impact Factor: 4.097**
18. **Drago L.**, Fassina MC, Mombelli B, De Vecchi E, Lombardi A, Gismondo MR. Comparative effect of thiamphenicol glycinate, thiamphenicol glycinate N-acetylcysteinate, amoxicillin plus clavulanic acid, ceftriaxone and clarithromycin on pulmonary clearance of *Haemophilus influenzae* in an animal model. *Chemotherapy* 2000, 46:275-81. **Impact Factor: 0.992**
19. **Drago L.**, Mombelli B, De Vecchi E, Fassina MC, Tocalli L, Gismondo MR. *In vitro* antimicrobial activity of propolis dry extract. *J Chemother* 2000, 12:390-5. **Impact Factor: 1.33**

20. **Drago L**, Mombelli B, De Vecchi E, Tocalli L, Nardi G, Gismondo MR. Epidemiology of Gram-negative antibiotic resistance in outpatients: a year of surveillance. *Int J Antimicrob Agents* 2000, 16:479-81. **Impact Factor: 4.097**
21. **Drago L**, Mombelli B, De Vecchi E, Bonaccorso C, Fassina MC, Gismondo MR. *Candida albicans* cellular internalization: a new pathogenic factor? *Int J Antimicrob Agents* 2000, 16:545-7. **Impact Factor: 4.097**
22. Lombardi A, **Drago L**, Bartolone MR, Gismondo MR. Cytomegalovirus pp65 antigenemia in HIV patients: retrospective on 3 years study. *Int J Antimicrob Agents* 2000, 16: 461-2. **Impact Factor: 4.097**
23. **Drago L**, De Vecchi E, Fassina MC, Mombelli B, Bonaccorso C, Gismondo MR. Antimycotic activity and phagocytosis effects of econazole in combination with ibuprofen isobuthanolammonium against vaginal strains. *J Chemother* 2000, 12:509-15. **Impact Factor: 1.33**
24. Zanchetta N, nardi G, Tocalli L, **Drago L**, Bossi C, Pulvirenti FR, Galli C, Gismondo MR. Evaluation of the Abbott Lcx HIV-1 RNA quantitative, a new assay for quantitative determination of human immunodeficiency virus type 1 RNA. *J Clin Microbiol* 2000, 38: 3882-6. **Impact Factor: 3.631**
25. **Drago L.**, De Vecchi E., Fassina M.C., Mombelli B., Tocalli L., Gismondo M.R. : "Comparative in vitro activity of Thiamphenicol-glycinate-acetyl-cysteinate and other Antimicrobials against Respiratory Pathogens." *Arzneim.-Forsch./Drug Res.*, 51 (1), 2001 : 315-324. **Impact Factor: 0.79**
26. Lombardi A, **Drago L**, De Vecchi E, Mombelli B, Gismondo MR. Antimicrobial activity of thiamphenicol-glycinate-acetylcysteinate and other drugs against *Chlamydia pneumoniae*. *Arzneim - Forsch/Drug Res* 2001, 51: 264-7. **Impact Factor: 0.79**
27. **L. Drago**, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo: Activity of levofloxacin and ciprofloxacin against urinary pathogens. *J Antimicrob Chemother* 2001, 48:37-45. **Impact Factor: 4.919**
28. **Drago L**, De Vecchi E, Valli M, Nicola L, Gismondo MR. Effect of linezolid in comparison with that of vancomycin on glycocalix production: in vitro study. *Antimicrob. Agents Chemother.* 2002. 46: 598-599. **Impact Factor: 4.415**
29. **Drago L**, De Vecchi E, Nicola L, Valli M, Gismondo MR. Effects of subinhibitory concentrations of ibuprofen isobuthanolammonium on virulence factors of uropathogenic *Escherichia coli*. *J Chemother* 14(3):314-5; 2002. **Impact Factor: 1.33**
30. **Drago L**, Lombardi A, De Vecchi E, Gismondo MR. Real-time PCR assay for rapid detection of *Bacillus anthracis* spores in clinical samples. *J Clin Microbiol.* 2002, 40: 4399. **Impact Factor: 3.631**
31. **Drago L**, De Vecchi E, Lombardi A, Nicola L, Valli M, Gismondo M.R. Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against *Bacillus anthracis* clinical isolates. *J Antimicrob Chemother* 2002, 50: 1059-1063. **Impact Factor: 4.919**
32. **Drago L**, De Vecchi E, Nicola L, Valli M, Marchetti F, Gismondo MR. Comparative bactericidal activity of fluoroquinolones against clinical isolates resistant to fluoroquinolones. *J Chemother* 2003, 15: 118-123. **Impact Factor: 1.33**
33. Marchisio P., Claut L., Rognoni A., Esposito S., Passali D., Bellussi L., **Drago L**. Pozzi G., Mannelli S., Schito G., Principi N. Differences in nasopharyngeal bacterial flora in children with nonsevere recurrent acute otitis media and chronic otitis media with effusion: implications for management. *Ped Infect Dis J.* 22(3):262-8, 2003 Mar. **Impact Factor: 2.587**
34. Blasi F, **Drago L**, Gismondo MR, Cosentini R, Tarsia P, Valenti V, Capone P, Allegra L. In vitro antibiotic activity against *Chlamydia pneumoniae* clinical isolates. *J Chemother.* 2003 Feb;15(1):93-4. **Impact Factor: 1.33**
35. **Drago L**, De Vecchi E, Nicola L, Tocalli L, Gismondo MR. Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone. *J Chemother*, 16(1):30-7, 2004. **Impact Factor: 1.33**
36. **Drago L**, De Vecchi E, Nicola L, Colombo A, Gismondo MR. Selection of resistance of telithromycin against *Haemophilus influenzae*, *Moraxella catarrhalis* and streptococci, in comparison with macrolides. *J Antimicrob Chemother* 2004; 54: 542-5. **Impact Factor: 4.919**
37. **Drago L**, De Vecchi E, Guerra A, Nicola L, Colombo A, Gismondo MR. Microbiological evaluation of commercial probiotic products available in Italy. *J Chemother*, 16(5):463-7, 2004. **Impact Factor: 1.33**

38. **Drago L**, De Vecchi E, Nicola L, Colombo A, Guerra A, Gismondo MR. Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin/tazobactam and amikacin against *Pseudomonas aeruginosa* different phenotypes and *Acinetobacter* spp. *Chemotherapy* , 50(4):202-10, 2004. **Impact Factor: 0.992**
39. **Drago L**, Lombardi A, De Vecchi E, Giuliani G, Bartolone R, Gismondo MR. :Comparison of nested PCR and real time PCR of Herpesvirus infections of central nervous system in HIV patients. *BMC Infect Dis.* 2004 Nov 30;4(1):55. **Impact Factor: 2.690**
40. **Drago L**, De Vecchi E, Nicola L, Legnani D, Lombardi A, Gismondo MR. In vitro synergy and selection of resistance by fluoroquinolones plus amikacin or beta-lactams against extended-spectrum beta-lactamase-producing *Escherichia coli*. *J Chemother.* 2005 Feb;17(1):46-53. **Impact Factor: 1.33**
41. **L. Drago**, E. De Vecchi, L. Nicola, M. Prenna, S. Ripa: *In vitro* selection of resistance to clarithromycin in *Streptococcus pneumoniae* clinical isolates. *J Chemother* 17 (2):161-168, 2005. **Impact Factor: 1.33**
42. **L. Drago**, E. De Vecchi, L. Nicola, M.R. Gismondo: Evaluation of antibacterial *in vitro* activity of moxifloxacin and its effects on pulmonary clearance of *Klebsiella pneumoniae* in an animal experimental model. *Arzneimittel und Forschung* 55(8):473-7, 2005. **Impact Factor: 0.79**
43. **L. Drago**, S. Ripa, C. Zampaloni, E. De Vecchi, L.A. Vitali, D. Petrelli, M. Prenna^a : Activity of ceftibuten, cefaclor, azithromycin, clarithromycin, erythromycin and telithromycin against *Streptococcus pyogenes* clinical isolates with different genotypes and phenotypes. *Chemotherapy*, Aug;51(5):268-71, 2005. **Impact Factor: 0.992**
44. **Drago L.**, De Vecchi, E., Nicola L., Tocalli L., Gismondo M.R.: In vitro selection of resistance in *Pseudomonas aeruginosa* and *Acinetobacter* spp. by levofloxacin and ciprofloxacin alone and in combination with β -lactams and amikacin. *J Antimicrob Chemother*, Aug;56(2):353-9, 2005. **Impact Factor: 4.919**
45. **Drago L.**, De Vecchi E, Nicola L., Legnani D., Gismondo M.R.: Kinetic bactericidal activity of telithromycin, azithromycin and clarithromycin against respiratory pathogens. *APMIS.* Oct;113(10):655-63, 2005. **Impact Factor: 1.933**
46. Amedeo F. Capetti, Alexandra I. Gabris, **Lorenzo Drago** and Gian Marco Vigevani: Can a K103N HIV strains stably overcome the wild type in the absence of non-nucleoside reverse transcriptase inhibitor selective pressure? *AIDS*, Vol 19, No 23, 2005. **Impact Factor: 4.407**
47. De Vecchi E, Nicola L, Zucchetti E, **Drago L**. In vitro induction of resistance by tissue concentrations of azithromycin, clarithromycin, cefixime and amoxicillin/clavulanate in clinical isolates of *Streptococcus pyogenes*. *J Chemother.* 2006 Aug;18(4):379-88. **Impact Factor: 1.33**
48. Esposito S, Noviello S, Leone S, Marvaso A, **Drago L**, Marchetti F; The LEVT06 Study Group. A pilot study on prevention of catheter-related urinary tract infections with fluoroquinolones. *J Chemother.* 2006 Oct;18(5):494-501. **Impact Factor: 1.33**
49. **Drago L**, De Vecchi E, Nicola L, Zucchetti E, Gismondo MR, Vicariotto F. Activity of a *Lactobacillus acidophilus*-based douche for the treatment of bacterial vaginosis. *J Altern Complement Med.* 2007 May;13(4):435-8. **Impact Factor: 1.395**
50. **Drago L**, De Vecchi E, Nicola L, Gismondo MR. In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant *Staphylococcus aureus* severe respiratory infections. *BMC Infect Dis.* 2007 Sep 21;7:111. **Impact Factor: 2.69**
51. **Drago L**, De Vecchi E, Nicola L, Gismondo MR. In vitro antimicrobial activity of a novel propolis formulation (Actichelated propolis). *J Appl Microbiol.* 2007 Nov;103(5):1914-21. **Impact Factor: 2.156**
52. **Drago L**, Esposito S, De Vecchi E, Marchisio P, Blasi F, Baggi E, Capaccio P, Pignataro L. Detection of respiratory viruses and atypical bacteria in children's tonsils and adenoids. *J Clin Microbiol.* 2008 Jan;46(1):369-70. **Impact Factor: 3.631**
53. De Vecchi E, Nicola L, Larosa M, **Drago L**. In vitro activity of telithromycin against *Haemophilus influenzae* at epithelial lining fluid concentrations. *BMC Microbiol.* 2008 Jan 29;8:23. **Impact Factor: 2.581**
54. **Drago L**, Nicola L, De Vecchi E. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in *Staphylococcus aureus* and *Enterococcus* spp. *Clin Microbiol Infect.* 2008 Jun;14(6):608-11. **Impact Factor: 4.575**

55. De Vecchi E, Nicola L, Zanini S, **Drago L**. In vitro screening of probiotics characteristics of some italian products. *J Chemother*. 2008 Vol 20 n° 3 (341-347). **Impact Factor: 1.33**
56. **Drago L**, Nicola L, Ossola F, De Vecchi E. In vitro antiviral activity of resveratrol against respiratory viruses. *J Chemother*. 2008, Vol 20 n° 3 (393-394). **Impact Factor: 1.33**
57. **Drago L**, De Vecchi E. The safety of cefepime in the treatment of infection. *Expert Opin Drug Saf*. 2008 July; 7(4):377-87. **Impact Factor: 2.896**
58. De Vecchi E, Nicola L, Ossola F, **Drago L**. In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations. *J Antimicrob Chemother*. 2009 Apr;63(4):721-7. **Impact Factor: 4.919**
59. Pignataro L, Torretta S, Pietrogrande MC, Dellepiane RM, Pavesi P, Bossi A, **Drago L**, Capaccio P. Outcome of tonsillectomy in selected patients with PFAPA syndrome. *Arch Otolaryngol Head Neck Surg*. 2009 Jun;135(6):548-53. **Impact Factor: 1.627**
60. **Drago L**, De Vecchi E, Airoidi A, Mattina R, Papazian B, Legnani D. Respiratory viruses in smokers and former smokers with exacerbations of chronic obstructive pulmonary disease. *J Chemother*. 2009 Aug;21(4):458-60. **Impact Factor: 1.33**
61. **Drago L**, De Vecchi E. Should Lactobacillus sporogenes and Bacillus coagulans have a future? *J Chemother*. 2009 Aug;21(4):371-7. **Impact Factor: 1.33**
62. Piacentini GL, Peroni DG, Blasi F, Pescollderung L, Goller P, Gallmetzer L, **Drago L**, Bodini A, Boner AL. Atypical bacteria in adenoids and tonsils of children requiring adenotonsillectomy. *Acta Otolaryngol*. 2010 May;130(5):620-5. **Impact Factor: 1.127**
63. Banfi G, **Drago L**, Lippi G. Analytical variability in athletes haematological testing. *Int J Sports Med*. 2010 Mar;31(3):218. **Impact Factor: 2.528**
64. **Drago L**, Nicola L, Mattina R, De Vecchi E. In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations. *BMC Microbiol*. 2010 Apr 21;10:119. **Impact Factor: 2.581**
65. Artini M, Romanò C, Manzoli L, Scoarughi GL, Papa R, Meani E, **Drago L**, Selan L. Staphylococcal IgM ELISA for the detection of peri-prosthetic joint infections. *J Clin Microbiol*. 2010 Nov 10. **Impact Factor: 3.631**
66. **Drago L**, Rodighiero V, Celeste T, De Vecchi E. Microbiological evaluation of commercial probiotic products available in the USA in 2009. *J Chemother*. 2010 Dec; 22(6):373-7. **Impact Factor: 1.33**
67. **Drago, Lorenzo**; Nicola, Lucia; Rodighiero, Valentina; Larosa, Monica; Mattina, Roberto; De Vecchi, Elena. Comparative evaluation of synergy of combinations of β -lactams with fluoroquinolones or macrolides in Streptococcus pneumoniae. *J Antimicrob Chemother*. 2011 Apr; 66(4):845-9. **Impact Factor: 4.919**
68. Romanò CL, Logoluso N, Dell'Oro F, Elia A, **Drago L**. Telethermographic findings after uncomplicated and septic total knee replacement. *Knee*. 2012 Jun;19(3):193-7. Epub 2011 Mar 26. **Impact Factor: 1.446**
69. Torretta S, **Drago L**, Marchisio P, Mattina R, Clemente IA, Pignataro L. Diagnostic accuracy of nasopharyngeal swabs in detecting biofilm-producing bacteria in chronic adenoiditis: A preliminary study. *Otolaryngol Head Neck Surg*. 2011 May; 144(5):784-8. **Impact Factor: 2.021**
70. Romanò CL, Romanò D, Meani E, Logoluso N, **Drago L**. Two-stage revision surgery with preformed spacers and cementless implants for septic hip arthritis: a prospective, non-randomized cohort study. *BMC Infect Dis*. 2011 May 16;11:129. **Impact Factor: 2.690**
71. **Drago L**, De Vecchi E, Pasqualini M, Moneghini L, Bruno M. Rapid, progressive neuropathic arthropathy of the hip in a patient co-infected with human immunodeficiency virus, hepatitis C virus and tertiary syphilis: case report. *BMC Infect Dis*. 2011 Jun 6;11:159. **Impact Factor: 2.690**
72. **Drago L**, Vassena C, Dozio E, Corsi MM, De Vecchi E, Mattina R, Romanò C. Procalcitonin, C-reactive protein, interleukin-6, and soluble intercellular adhesion molecule-1 as markers of postoperative orthopaedic joint prosthesis infections. *Int J Immunopathol Pharmacol*. 2011 Apr-Jun;24(2):433-40. **Impact Factor: 1.617**
73. **Drago L**, Rodighiero V, Mattina R, Toscano M, De Vecchi E. In vitro selection of antibiotic resistance in the probiotic strain *Lactobacillus rhamnosus* GG ATCC 53103. *J Chemother*. 2011 Aug;23(4):211-5. **Impact Factor: 1.33**

74. **Drago L**, Mattina R, Nicola L, Rodighiero V, De Vecchi E. Macrolide resistance and in vitro selection of resistance to antibiotics in *Lactobacillus* isolates. *J Microbiol*. 2011 Aug;49(4):651-6. **Impact Factor: 1.621**
75. **Drago L**, Mattina R, Legnani D, Romano CL, Vianello E, Ricci C, De Vecchi E. Modulation of biofilm of strains isolated from patients with chronic obstructive pulmonary disease by levofloxacin, moxifloxacin, ciprofloxacin, amoxicillin/clavulanic acid and ceftriaxone. *Int J Immunopathol Pharmacol*. 2011 Oct-Dec;24(4):1027-35. **Impact Factor: 1.617**
76. **Drago L**, Iemoli E, Rodighiero V, Nicola L, De Vecchi E, Piconi S. Effects of *Lactobacillus salivarius* LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study. *Int J Immunopathol Pharmacol*. 2011 Oct-Dec;24(4):1037-48. **Impact Factor: 1.617**
77. **Drago L**, Rodighiero V, Mattina R, Toscano M, DE Vecchi E. In vitro selection and transferability of antibiotic resistance in the probiotic strain *Lactobacillus reuteri* DSM 17938. *J Chemother*. 2011 Dec;23(6):371-3. **Impact Factor: 1.33**
78. Romanò CL, Gala L, Logoluso N, Romanò D, **Drago L**. Two-stage revision of septic knee prosthesis with articulating knee spacers yields better infection eradication rate than one-stage or two-stage revision with static spacers. *Knee Surg Sports Traumatol Arthrosc*. 2012 Jan 21. **Impact Factor: 3.097**
79. Torretta S, Marchisio P, **Drago L**, Baggi E, De Vecchi E, Garavello W, Nazzari E, Pignataro L, Esposito S. Nasopharyngeal biofilm-producing otopathogens in children with nonsevere recurrent acute otitis media. *Otolaryngol Head Neck Surg*. 2012 Jun;146(6):991-6. Epub 2012 Feb 21. **Impact Factor: 2.021**
80. **Drago L**, De Vecchi E, Torretta S, Mattina R, Marchisio P, Pignataro L. Biofilm formation by bacteria isolated from upper respiratory tract before and after adenotonsillectomy. *APMIS*. 2012 May;120(5):410-6. **Impact Factor: 1.933**
81. **Drago L**, Romanò CL, Mattina R, Signori V, De Vecchi E. Does dithiothreitol improve bacterial detection from infected prostheses? A pilot study. *Clin Orthop Relat Res*. 2012 Oct;470(10):2915-25. **Impact Factor: 3.127**
82. Iemoli E, Trabattoni D, Parisotto S, Borgonovo L, Toscano M, Rizzardini G, Clerici M, Ricci E, Fusi A, De Vecchi E, Piconi S, **Drago L**. Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. *J Clin Gastroenterol*. 2012 Oct;46 Suppl:S33-40. **Impact Factor: 3.163**
83. **Drago L**, Toscano M, De Vecchi E, Piconi S, Iemoli E. Changing of Fecal Flora and Clinical Effect of *L. salivarius* LS01 in Adults With Atopic Dermatitis. *J Clin Gastroenterol*. 2012 Oct;46 Suppl:S56-63. **Impact Factor: 3.163**
84. **Drago L**, Toscano M, Rodighiero V, De Vecchi E, Mogna G. Cultivable and pyrosequenced fecal microflora in centenarians and young subjects. *J Clin Gastroenterol*. 2012 Oct;46 Suppl:S81-4. **Impact Factor: 3.163**
85. Galliera E, Luzzati A, Perrucchini G, Gagliano F, Colloredo Mels L, Banfi G, Corsi Romanelli MM, **Drago L**. Bone formation and resorption markers as diagnostic tools for bone metastases evaluation. *Int J Biol Markers*. 2012 Sep 17:0. doi:10.5301/JBM.2012.9579. **Impact Factor: 1.217**
86. Torretta S, **Drago L**, Marchisio P, Cappadona M, Rinaldi V, Nazzari E, Pignataro L. Recurrences in chronic tonsillitis substained by tonsillar biofilm-producing bacteria in children. Relationship with the grade of tonsillar hyperplasy. *Int J Pediatr Otorhinolaryngol*. 2013 Feb;77(2):200-4. **Impact Factor: 1.125**
87. **Drago L**, De Vecchi E, Mattina R, Romanò CL. Activity of N-acetyl-L-cysteine against biofilm of *Staphylococcus aureus* and *Pseudomonas aeruginosa* on orthopaedic prosthetic materials. *Int J Artif Organs*. 2013 Jan;36(1):39-46. **Impact Factor: 1.005**
88. Galliera E, Dozio E, Dogliotti G, Vassena C, Colloredo Mels L, Romano CL, Mattina R, Corsi MM, **Drago L**. Iron status evaluation as a marker of postoperative joint infection: a pilot study. *Int J Immunopathol Pharmacol*. 2012 Oct-Dec;25(4):1149-55. **Impact Factor: 1.617**
89. **Drago L**, Mattina R, De Vecchi E, Toscano M. Phenotypic and genotypic antibiotic resistance in some probiotics proposed for medical use. *Int J Antimicrob Agents*. 2013 Apr;41(4):396-7. **Impact Factor: 4.097**
90. **Drago L**, Bortolin M, Vassena C, Taschieri S, Del Fabbro M. Antimicrobial activity of pure platelet-rich plasma against microorganisms isolated from oral cavity. *BMC Microbiol*. 2013 Feb 25;13:47. **Impact Factor: 2.581**

91. De Vecchi E, Sitia S, Romanò CL, Ricci C, Mattina R, **Drago L**. Aetiology and antibiotic resistance patterns of urinary tract infections in the elderly: a 6-month study. *J Med Microbiol*. 2013 Jun;62(Pt 6):859-63. **Impact Factor: 2.269**
92. Torretta S, **Drago L**, Marchisio P, Gaffuri M, Clemente IA, Pignataro L. Topographic distribution of biofilm-producing bacteria in adenoid subsites of children with chronic or recurrent middle ear infections. *Ann Otol Rhinol Laryngol*. 2013 Feb;122(2):109-13. **Impact Factor: 1.171**
93. Romanò CL, Toscano M, Romanò D, **Drago L**. Antibiofilm agents and implant-related infections in orthopaedics: where are we? *J Chemother*. 2013 Apr;25(2):67-80. **Impact Factor: 1.33**
94. **Drago L**, De Vecchi E, Romano' CL, Vassena C, Banfi G. Behaviour of perioperative values of haemoglobin, haematocrit and red blood cells in elderly patients undergoing lower limb arthroplasty: a retrospective cohort study on non-transfused patients. *Int J Immunopathol Pharmacol*. 2013 Apr-Jun;26(2):427-33. **Impact Factor: 1.617**
95. Toscano M, de Vecchi E, Rodighiero V, **Drago L**. Microbiological and genetic identification of some probiotics proposed for medical use in 2011. *J Chemother*. 2013;25(3):156-61. **Impact Factor: 1.33**
96. **Drago L**, Signori V, De Vecchi E, Vassena C, Palazzi E, Cappelletti L, Romanò D, Romanò CL. Use of dithiothreitol to improve the diagnosis of prosthetic joint infections. *J Orthop Res*. 2013 Jul 2. **Impact Factor: 2.807**
97. Lovati AB, **Drago L**, Monti L, De Vecchi E, Previdi S, Banfi G, Romanò CL. Diabetic mouse model of orthopaedic implant-related *Staphylococcus aureus* infection. *PLoS One*. 2013 Jun 20;8(6):e67628. **Impact Factor: 3.057**
98. **Drago L**, Vassena C, Saibene AM, Del Fabbro M, Felisati G. A case of coinfection in a chronic maxillary sinusitis of odontogenic origin: identification of *Dialister pneumosintes*. *J Endod*. 2013 Aug;39(8):1084-7. **Impact Factor: 2.904**
99. Drago L, Toscano M, Pigatto PD. Probiotics: immunomodulatory properties in allergy and eczema. *G Ital Dermatol Venereol*. 2013 Oct;148(5):505-14. **Impact factor: 1.014**
100. Veraldi S, Nazzaro G, Cuka E, **Drago L**. Anthrax of the lower lip. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2013 Oct 10. **Impact Factor: 1.262**
101. Di Nardo G, Barbara G, Cucchiara S, Cremon C, Shulman RJ, Isoldi S, Zecchi L, **Drago L**, Oliva S, Saulle R, Barbaro MR, Stronati L. Neuroimmune interactions at different intestinal sites are related to abdominal pain symptoms in children with IBS. *Neurogastroenterol Motil*. 2014 Feb;26(2):196-204. **Impact Factor: 3.310**
102. **Drago L**, Romanò D, De Vecchi E, Vassena C, Logoluso N, Mattina R, Romanò CL. Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study. *BMC Infect Dis*. 2013 Dec 10;13:584. **Impact Factor: 2.690**
103. Scarponi S, **Drago L**, Romanò D, Logoluso N, Peccati A, Meani E, Romanò CL. Cementless modular intramedullary nail without bone-on-bone fusion as a salvage procedure in chronically infected total knee prosthesis: long-term results. *Int Orthop*. 2014 Feb;38(2):413-8. **Impact Factor: 2.387**
104. Zmistowski B, Della Valle C, Bauer TW, Malizos KN, Alavi A, Bedair H, Booth RE, Choong P, Deirmengian C, Ehrlich GD, Gambir A, Huang R, Kissin Y, Kobayashi H, Kobayashi N, Krenn V, **Drago L**, Marston SB, Meermans G, Perez J, Ploegmakers JJ, Rosenberg A, Simpendorfer C, Thomas P, Tohtz S, Villafuerte JA, Wahl P, Wagenaar FC, Witzo E. Diagnosis of periprosthetic joint infection. *J Arthroplasty*. 2014 Feb;29(2 Suppl):77-83. **Impact Factor: 2.515**
105. Galliera E, Drago L, Vassena C, Romanò C, Gioia Marazzi M, Salcito L, Corsi Romanelli MM. Toll-like receptor 2 in serum: a potential diagnostic marker of prosthetic joint infection? *J Clin Microbiol*. 2014 Feb;52(2):620-3. **Impact Factor: 3.631**
106. Atzeni F, Sarzi-Puttini P, Signorello MC, Gianturco L, Stella D, Boccassini L, Ricci C, Bodini BD, Batticciotto A, De Gennaro-Colonna V, **Drago L**, Turiel M. New parameters for identifying subclinical atherosclerosis in patients with primary Sjögren's syndrome: a pilot study. *Clin Exp Rheumatol*. 2014 May-Jun;32(3):361-8. **Impact Factor: 2.495**
107. **Drago L**, Boot W, Dimas K, Malizos K, Hänsch GM, Stuyck J, Gawlitta D, Romanò CL. Does implant coating with antibacterial-loaded hydrogel reduce bacterial colonization and biofilm formation in vitro? *Clin Orthop Relat Res*. 2014 Nov;472(11):3311-23. **Impact Factor: 3.127**

108. **Drago L**, Cappelletti L, De Vecchi E, Pignataro L, Torretta S, Mattina R. Antiadhesive and antibiofilm activity of hyaluronic acid against bacteria responsible for respiratory tract infections. *APMIS*. 2014 Oct;122(10):1013-9. **Impact Factor: 1.933**
109. Lovati AB, Romanò CL, Monti L, Vassena C, Previdi S, **Drago L**. Does PGE₁ vasodilator prevent orthopaedic implant-related infection in diabetes? Preliminary results in a mouse model. *PLoS One*. 2014 Apr 9;9(4). **Impact Factor: 3.057**
110. Romanò C, Logoluso N, **Drago L**, Peccati A, Romanò D. Role for irrigation and debridement in periprosthetic infections. *J Knee Surg*. 2014 Aug;27(4):267-72. **Impact Factor: 1.50**
111. **Drago L**, Vassena C, Fenu S, De Vecchi E, Signori V, De Francesco R, Romanò CL. In vitro antibiofilm activity of bioactive glass S53P4. *Future Microbiol*. 2014;9(5):593-601. **Impact Factor: 3.637**
112. **Drago L**, De Vecchi E, Cappelletti L, Mattina R, Vassena C, Romanò CL. Role and antimicrobial resistance of staphylococci involved in prosthetic joint infections. *Int J Artif Organs*. 2014 May;37(5):414-21. **Impact Factor: 1.005**
113. Romanò CL, Monti L, Logoluso N, Romanò D, **Drago L**. Does a thrombin-based topical haemostatic agent reduce blood loss and transfusion requirements after total knee revision surgery? A randomized, controlled trial. *Knee Surg Sports Traumatol Arthrosc*. 2015 Nov;23(11):3337-42. **Impact Factor: 3.097**
114. **Drago L**, Del Fabbro M, Bortolin M, Vassena C, De Vecchi E, Taschieri S. Biofilm removal and antimicrobial activity of two different air-polishing powders: an in vitro study. *J Periodontol*. 2014 Nov;85(11). **Impact Factor: 2.844**
115. **Drago L**, Bortolin M, Vassena C, Romanò CL, Taschieri S, Del Fabbro M. Plasma components and platelet activation are essential for the antimicrobial properties of autologous platelet-rich plasma: an in vitro study. *PLoS One*. 2014 Sep 18;9(9). **Impact Factor: 3.057**
116. Niccoli AA, Artesi AL, Candio F, Ceccarelli S, Cozzali R, Ferraro L, Fiumana D, Mencacci M, Morlupo M, Pazzelli P, Rossi L, Toscano M, **Drago L**. Preliminary results on clinical effects of probiotic *Lactobacillus salivarius* LS01 in children affected by atopic dermatitis. *J Clin Gastroenterol*. 2014 Nov-Dec;48 Suppl 1:S34-6. **Impact Factor: 3.163**
117. **Drago L**, De Vecchi E, Toscano M, Vassena C, Altomare G, Pigatto P. Treatment of atopic dermatitis eczema with a high concentration of *Lactobacillus salivarius* LS01 associated with an innovative gelling complex: a pilot study on adults. *J Clin Gastroenterol*. 2014 Nov-Dec;48 Suppl 1:S47-51. **Impact Factor: 3.163**
118. Maroni P, Matteucci E, **Drago L**, Banfi G, Bendinelli P, Desiderio MA. Hypoxia induced E-cadherin involving regulators of Hippo pathway due to HIF-1 α stabilization/nuclear translocation in bone metastasis from breast carcinoma. *Exp Cell Res*. 2015 Jan 15;330(2):287-99. **Impact Factor: 3.378**
119. Galliera E, **Drago L**, Marazzi MG, Romanò C, Vassena C, Corsi Romanelli MM. Soluble urokinase-type plasminogen activator receptor (suPAR) as new biomarker of the prosthetic joint infection: correlation with inflammatory cytokines. *Clin Chim Acta*. 2015 Feb 20;441:23-8. **Impact Factor: 2.799**
120. Torretta S, Marchisio P, **Drago L**, Capaccio P, Baggi E, Pignataro L. The presence of biofilm-producing bacteria on tonsils is associated with increased exhaled nitric oxide levels: preliminary data in children who experience recurrent exacerbations of chronic tonsillitis. *J Laryngol Otol*. 2015 Mar;129(3):267-72. **Impact Factor: 0.736**
121. **Drago L**, De Vecchi E, Gabrieli A, De Grandi R, Toscano M. Immunomodulatory Effects of *Lactobacillus salivarius* LS01 and *Bifidobacterium breve* BR03, Alone and in Combination, on Peripheral Blood Mononuclear Cells of Allergic Asthmatics. *Allergy Asthma Immunol Res*. 2015 Jul;7(4):409-13. **Impact Factor: 2.309**
122. Gianturco L, Bodini BD, Atzeni F, Colombo C, Stella D, Sarzi-Puttini P, **Drago L**, Galaverna S, Turiel M. Cardiovascular and autoimmune diseases in females: The role of microvasculature and dysfunctional endothelium. *Atherosclerosis*. 2015 Jul;241(1):259-63. **Impact Factor: 3.942**
123. **Drago L**, De Vecchi E, Cappelletti L, Vassena C, Toscano M, Bortolin M, Mattina R, Romanò CL. Prolonging culture to 15 days improves bacterial detection in bone and joint infections. *Eur J Clin Microbiol Infect Dis*. 2015 Sep;34(9):1809-13. **Impact Factor: 2.857**

124. **Drago L**, De Vecchi E, Bortolin M, Toscano M, Mattina R, Romanò CL. Antimicrobial activity and resistance selection of different bioglass S53P4 formulations against multidrug resistant strains. *Future Microbiol.* 2015;10(8):1293-9. **Impact Factor: 3.637**
125. Signori V, Romanò CL, De Vecchi E, Mattina R, **Drago L**. May osteoarticular infections be influenced by vitamin D status? An observational study on selected patients. *BMC Musculoskelet Disord.* 2015 Aug 5;16:183. **Impact Factor: 1.684**
126. Saibene AM, Vassena C, Pipolo C, Trimboli M, De Vecchi E, Felisati G, **Drago L**. Odontogenic and rhinogenic chronic sinusitis: a modern microbiological comparison. *Int Forum Allergy Rhinol.* 2015 Sep 8. **Impact Factor: 2.082**
127. Romanò CL, Scarponi S, Gallazzi E, Romanò D, **Drago L**. Antibacterial coating of implants in orthopaedics and trauma: a classification proposal in an evolving panorama. *J Orthop Surg Res.* 2015 Oct 1;10(1):157. **Impact Factor: 1.215**
128. Bortolin M, De Vecchi E, Romanò CL, Toscano M, Mattina R, **Drago L**. Antibiofilm agents against MDR bacterial strains: is bioactive glass BAG-S53P4 also effective? *J Antimicrob Chemother.* 2015 Oct 12. **Impact Factor: 4.919**
129. Maroni P, Bendinelli P, Morelli D, **Drago L**, Luzzati A, Perruchini G, Bonini C, Matteucci E, Desiderio MA. High SPARC Expression Starting from Dysplasia, Associated with Breast Carcinoma, Is Predictive for Bone Metastasis without Enhancement of Plasma Levels. *Int J Mol Sci.* 2015 Nov 26;16(12):28108-22. **Impact Factor: 3.257**
130. **Drago L**, Cappelletti L, Lamartina C, Berjano P, Mattina R, De Vecchi E. Colonization by methicillin resistant staphylococci of nares and skin in healthcare workers: a pilot study in spinal surgeries. *Injury.* 2015 Dec;46 Suppl 8:S77-80. **Impact Factor: 1.910**
131. Garantziotis S, Brezina M, Castelnuovo P, **Drago L**. The role of hyaluronan in the pathobiology and treatment of respiratory disease. *Am J Physiol Lung Cell Mol Physiol.* 2016 May 1;310(9):L785-95. **Impact Factor: 4.721**
132. Lovati AB, Romanò CL, Bottagisio M, Monti L, De Vecchi E, Previdi S, Accetta R, **Drago L**. Modeling *Staphylococcus epidermidis*-Induced Non-Unions: Subclinical and Clinical Evidence in Rats. *PLoS One.* 2016 Jan 21;11(1):e0147447. **Impact Factor: 3.057**
133. **Drago L**, De Grandi R, Altomare G, Pigatto P, Rossi O, Toscano M. Skin microbiota of first cousins affected by psoriasis and atopic dermatitis. *Clin Mol Allergy.* 2016 Jan 25;14:2. **Impact Factor: 2.860**
134. **Drago L**, Agrappi S, Bortolin M, Toscano M, Romanò CL, De Vecchi E. How to Study Biofilms after Microbial Colonization of Materials Used in Orthopaedic Implants. *Int J Mol Sci.* 2016 Feb 26;17(3):293. **Impact Factor: 3.257**
135. **Drago L**, De Grandi R, De Vecchi E, Toscano M. Antibiotic susceptibility profile of a new *Lactobacillus kefir* strain. *J Glob Antimicrob Resist.* 2016 Mar;4:74-75. **Impact Factor: 1.276**
136. **Drago L**, Lidgren L, Bottinelli E, Villafañe JH, Berjano P, Banfi G, Romanò CL, Sculco TP. Mapping of Microbiological Procedures by the Members of the International Society of Orthopaedic Centers (ISOC) for Diagnosis of Periprosthetic Infections. *J Clin Microbiol.* 2016 May;54(5):1402-3. **Impact Factor: 3.631**
137. **Drago L**, Toscano M, De Grandi R, Casini V, Pace F. Persisting changes of intestinal microbiota after bowel lavage and colonoscopy. *Eur J Gastroenterol Hepatol.* 2016 May;28(5):532-7. **Impact Factor: 2.093**
138. **Drago L**, Bortolin M, De Vecchi E, Agrappi S, Weinstein RL, Mattina R, Francetti L. Antibiofilm activity of sandblasted and laser-modified titanium against microorganisms isolated from peri-implantitis lesions. *J Chemother.* 2016 May 30:1-7. **Impact Factor: 1.33**
139. De Vecchi E, Bortolin M, Signori V, Romanò CL, **Drago L**. Treatment With Dithiothreitol Improves Bacterial Recovery From Tissue Samples in Osteoarticular and Joint Infections. *J Arthroplasty.* 2016 May 11. **Impact Factor: 2.515**
140. Sgambelluri F, Diani M, Altomare A, Frigerio E, **Drago L**, Granucci F, Banfi G, Altomare G, Reali E. A role for CCR5(+)CD4 T cells in cutaneous psoriasis and for CD103(+) CCR4(+) CD8 T eff cells in the associated systemic inflammation. *J Autoimmun.* 2016 Jun;70:80-90. **Impact Factor: 7.760**
141. De Vecchi E, Villa F, Bortolin M, Toscano M, Tacchini L, Romanò CL, **Drago L**. Leucocyte esterase, glucose and C-reactive protein in the diagnosis of prosthetic joint infections: a prospective study. *Clin Microbiol Infect.* 2016 Jun;22(6):555-60. **Impact Factor: 5.292**

142. Galliera E, Marazzi MG, **Drago L**, Banfi G, Luzzati A, Corsi Romanelli MM. Wnt signaling pathway inhibitors as promising diagnostic serum markers of osteolytic bone metastasis. *J Biol Regul Homeost Agents*. 2016 Apr-Jun;30(2):399-408. **Impact Factor: 1.360**
143. De Vecchi E, Bottagisio M, Bortolin M, Toscano M, Lovati AB, **Drago L**. Improving the Bacterial Recovery by Using Dithiothreitol with Aerobic and Anaerobic Broth in Biofilm-Related Prosthetic and Joint Infections. *Adv Exp Med Biol*. 2016 Jul 12. **Impact Factor: 1.953**
144. Balestri E, Villafaña JH, Bertozzi L, Berlini S, Rocino A, Paganoni AM, **Drago L**, Berjano P. Validation of the Italian Version of the Haemophilia Activities List. *Acta Haematol*. 2016;136(3):152-6. **Impact Factor: 1.20**
145. Lovati AB, **Drago L**, Bottagisio M, Bongio M, Ferrario M, Perego S, Sansoni V, De Vecchi E, Romanò CL. Systemic and Local Administration of Antimicrobial and Cell Therapies to Prevent Methicillin-Resistant Staphylococcus epidermidis-Induced Femoral Nonunions in a Rat Model. *Mediators Inflamm*. 2016;2016:9595706. **Impact Factor: 3.232**
146. Torretta S, Marchisio P, Rinaldi V, Gaffuri M, Pascariello C, **Drago L**, Baggi E, Pignataro L. Topical administration of hyaluronic acid in children with recurrent or chronic middle ear inflammations. *Int J Immunopathol Pharmacol*. 2016 Sep;29(3):438-42. **Impact Factor: 2.347**
147. Berjano P, Villafaña JH, Lo Re D, Ismael M, Damilano M, Bertozzi L, Romanò CL, **Drago L**. Is propionibacterium acnes related to disc degeneration in adults? A systematic review. *J Neurosurg Sci*. 2016 Sep 7. **Impact Factor: 1.522**
148. Calori GM, Colombo M, Navone P, Nobile M, Auxilia F, Toscano M, **Drago L**. Comparative evaluation of MicroDTTect device and flocked swabs in the diagnosis of prosthetic and orthopaedic infections. *Injury*. 2016 Oct;47 Suppl 4:S17-S21. **Impact Factor: 1.894**
149. George DA, Logoluso N, Castellini G, Gianola S, Scarponi S, Haddad FS, **Drago L**, Romano CL. Does cemented or cementless single-stage exchange arthroplasty of chronic periprosthetic hip infections provide similar infection rates to a two-stage? A systematic review. *BMC Infect Dis*. 2016 Oct 10;16(1):553. **Impact Factor: 2.768**
150. Ottria R, Cappelletti L, Ravelli A, Mariotti M, Gigli F, Romagnoli S, Ciuffreda P, Banfi G, **Drago L**. Plasma endocannabinoid behaviour in total knee and hip arthroplasty. *J Biol Regul Homeost Agents*. 2016 Oct-Dec;30(4):1147-1152. **Impact Factor: 1.360**
151. Galliera E, Marazzi MG, Vianello E, **Drago L**, Luzzati A, Bendinelli P, Maroni P, Tacchini L, Desiderio MA, Corsi Romanelli MM. Circulating sRAGE in the diagnosis of osteolytic bone metastasis. *J Biol Regul Homeost Agents*. 2016 Oct-Dec;30(4):1203-1208. **Impact Factor: 1.360**
152. Lovati AB, Bottagisio M, de Vecchi E, Gallazzi E, **Drago L**. Animal Models of Implant-Related Low-Grade Infections. A Twenty-Year Review. *Adv Exp Med Biol*. 2017; 971:29-50. **Impact Factor: 2.210**
153. Romanò CL, Romanò D, Morelli I, **Drago L**. The Concept of Biofilm-Related Implant Malfunction and "Low-Grade Infection". *Adv Exp Med Biol*. 2017;971:1-13. **Impact Factor: 2.210**
154. **Drago L**, De Vecchi E. Microbiological Diagnosis of Implant-Related Infections: Scientific Evidence and Cost/Benefit Analysis of Routine Antibiofilm Processing. *Adv Exp Med Biol*. 2017;971:51-67. **Impact Factor: 2.210**
155. Toscano M, De Grandi R, Miniello VL, Mattina R, **Drago L**. Ability of Lactobacillus kefir LKF01 (DSM32079) to colonize the intestinal environment and modify the gut microbiota composition of healthy individuals. *Dig Liver Dis*. 2017 Mar;49(3):261-267. **Impact Factor: 3.061**
156. **Drago L**, Toscano M, De Grandi R, Grossi E, Padovani EM, Peroni DG. Microbiota network and mathematic microbe mutualism in colostrum and mature milk collected in two different geographic areas: Italy versus Burundi. *ISME J*. 2017 Apr;11(4):875-884. **Impact Factor: 9.664**
157. Morelli I, **Drago L**, George DA, Gallazzi E, Scarponi S, Romanò CL. Masquelet technique: myth or reality? A systematic review and meta-analysis. *Injury*. 2016 Dec;47 Suppl 6:S68-S76. **Impact Factor: 1.894**
158. Romanò CL, De Vecchi E, Bortolin M, Morelli I, **Drago L**. Hyaluronic Acid and Its Composites as a Local Antimicrobial/Anti-adhesive Barrier. *J Bone Jt Infect*. 2017 Jan 1;2(1):63-72. **Impact Factor: 1.610**
159. Gallazzi E, **Drago L**, Baldini A, Stockley I, George DA, Scarponi S, Romanò CL. Combined Diagnostic Tool" APPLication to a Retrospective Series of Patients Undergoing Total Joint Revision Surgery. *J Bone Jt Infect*. 2017 Feb 4;2(2):107-113. **Impact Factor: 1.610**

- Drago L**, Arts JJ, Juutilainen V, Hyvönen P, Suda AJ, Domenico A, Artiaco S, Alizadeh C, Brychey A, Bialecki J, Romanò CL. Antibacterial Bioactive Glass, S53P4, for Chronic Bone Infections - A Multinational Study. *Adv Exp Med Biol*. 2017;971:81-92. **Impact Factor: 2.210**
160. **Drago L**, Romanò CL, Cecchinato R, Villafañe JH, De Vecchi E, Lamartina C, Berjano P. Are MODIC Type 2 disc changes associated with low-grade infections? A pilot study. *J Neurosurg Sci*. 2017 Feb 15. **Impact Factor: 1.522**
161. Morelli I, **Drago L**, George DA, Romanò D, Romanò CL. Managing large bone defects in children: a systematic review of the 'induced membrane technique'. *J Pediatr Orthop B*. 2017 Mar 31. **Impact Factor: 0.938**
162. Toscano M, De Grandi R, Stronati L, De Vecchi E, **Drago L**. Effect of *Lactobacillus rhamnosus* HN001 and *Bifidobacterium longum* BB536 on the healthy gut microbiota composition at phyla and species level: A preliminary study. *World J Gastroenterol*. 2017 Apr 21;23(15):2696-2704. **Impact Factor: 3.365**
163. Bottagisio M, Soggiu A, Lovati AB, Toscano M, Piras C, Romanò CL, Bonizzi L, Roncada P, **Drago L**. Draft Genome Sequence of *Staphylococcus epidermidis* Clinical Strain GOI1153754-03-14 Isolated from an Infected Knee Prosthesis. *Genome Announc*. 2017 May 18;5(20). pii: e00378-17. **Impact Factor: 1.180**
164. George DA, **Drago L**, Scarponi S, Gallazzi E, Haddad FS, Romano CL. Predicting lower limb periprosthetic joint infections: A review of risk factors and their classification. *World J Orthop*. 2017 May 18;8(5):400-411. **Impact Factor: 2.200**
165. Bortolin M, Bidossi A, De Vecchi E, Avveniente M, **Drago L**. In vitro Antimicrobial Activity of Chlorquinaldol against Microorganisms Responsible for Skin and Soft Tissue Infections: Comparative Evaluation with Gentamicin and Fusidic Acid. *Front Microbiol*. 2017 Jun 8;8:1039. **Impact Factor: 4.076**
166. Malizos K, Blauth M, Danita A, Capuano N, Mezzoprete R, Logoluso N, **Drago L**, Romanò CL. Fast-resorbable antibiotic-loaded hydrogel coating to reduce post-surgical infection after internal osteosynthesis: a multicenter randomized controlled trial. *J Orthop Traumatol*. 2017 Jun;18(2):159-169. **Impact Factor: 1.280**
167. Pellegata AF, Bottagisio M, Boschetti F, Ferroni M, Bortolin M, **Drago L**, Lovati AB. Terminal sterilization of equine-derived decellularized tendons for clinical use. *Mater Sci Eng C Mater Biol Appl*. 2017 Jun 1;75:43-49. **Impact Factor: 4.164**
168. Diani M, Galasso M, Cozzi C, Sgambelluri F, Altomare A, Cigni C, Frigerio E, **Drago L**, Volinia S, Granucci F, Altomare G, Reali E. Blood to skin recirculation of CD4+ memory T cells associates with cutaneous and systemic manifestations of psoriatic disease. *Clin Immunol*. 2017 Jul;180:84-94. **Impact Factor: 3.990**
169. Romanò CL, Malizos K, Capuano N, Mezzoprete R, D'Arienzo M, Van Der Straeten C, Scarponi S, **Drago L**. Does an Antibiotic-Loaded Hydrogel Coating Reduce Early Post-Surgical Infection After Joint Arthroplasty? *J Bone Jt Infect*. 2016 Jul 19;1:34-41. **Impact Factor: 1.610**
170. Bidossi A, Bortolin M, Toscano M, De Vecchi E, Romanò CL, Mattina R, **Drago L**. In vitro comparison between α -tocopheryl acetate and α -tocopheryl phosphate against bacteria responsible of prosthetic and joint infections. *PLoS One*. 2017 Jul 31;12(7):e0182323. **Impact Factor: 3.540**
171. **Drago L**, De Vecchi E, Bortolin M, Zagra L, Romanò CL, Cappelletti L. Epidemiology and Antibiotic Resistance of Late Prosthetic Knee and Hip Infections. *J Arthroplasty*. 2017 Aug;32(8):2496-2500. **Impact Factor: 3.055**
172. Toscano M, De Grandi R, Peroni DG, Grossi E, Facchin V, Comberiat P, **Drago L**. Impact of delivery mode on the colostrum microbiota composition. *BMC Microbiol*. 2017 Sep 25;17(1):205. **Impact Factor: 2.644**
173. **Drago L**, Bortolin M, Taschieri S, De Vecchi E, Agrappi S, Del Fabbro M, Francetti L, Mattina R. Erythritol/chlorhexidine combination reduces microbial biofilm and prevents its formation on titanium surfaces in vitro. *J Oral Pathol Med*. 2017 Sep;46(8):625-631. **Impact Factor: 2.043**
174. Villa F, Toscano M, De Vecchi E, Bortolin M, **Drago L**. Reliability of a multiplex PCR system for diagnosis of early and late prosthetic joint infections before and after broth enrichment. *Int J Med Microbiol*. 2017 Sep;307(6):363-370. **Impact Factor: 3.391**

175. Logoluso N, **Drago L**, Gallazzi E, George DA, Morelli I, Romanò CL. Calcium-Based, Antibiotic-Loaded Bone Substitute as an Implant Coating: A Pilot Clinical Study. *J Bone Jt Infect*. 2016 Oct 1;1:59-64. **Impact Factor: 1.610**
176. Toscano M, De Grandi R, Grossi E, **Drago L** Role of the Human Breast Milk-Associated Microbiota on the Newborns' Immune System: A Mini Review. *Front Microbiol*. 2017 Oct 25;8:2100. **Impact Factor: 4.076**
177. **Drago L**, Toscano M, Tacchini L, Banfi G. α -Defensin point-of-care test for diagnosis of prosthetic joint infections: neglected role of laboratory and clinical pathologists. *Clin Chem Lab Med*. 2017 Nov 27;56(1):19-24. **Impact Factor:3.432**
178. Toscano M, De Grandi R, Pastorelli L, Vecchi M, **Drago L**. A consumer's guide for probiotics: 10 golden rules for a correct use. *Dig Liver Dis*. 2017 Nov;49(11):1177-1184. **Impact Factor: 3.061**
179. **Drago L**, Micali G, Papini M, Piraccini BM, Veraldi S. Management of mycoses in daily practice. *G Ital Dermatol Venereol*. 2017 Dec;152(6):642-650. **Impact Factor: 1.311**
180. Marazzi MG, Randelli F, Brioschi M, **Drago L**, Romanò CL, Banfi G, Massaccesi L, Crapanzano C, Morelli F, Corsi Romanelli MM, Galliera E. Presepsin: A potential biomarker of PJI? A comparative analysis with known and new infection biomarkers. *Int J Immunopathol Pharmacol*. 2017 Dec 1:394632017749356. **Impact Factor: 2.347**.
181. Romanò CL, Morelli I, Romanò D, Meani E, Drago L. ICS classification system of infected osteosynthesis: Long-term results. *Injury*. 2018 Mar;49(3):564-569.
182. Nobili V, Putignani L, Mosca A, Chierico FD, Vernocchi P, Alisi A, Stronati L, Cucchiara S, Toscano M, **Drago L**. Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players? *Arch Med Sci*. 2018 Jan;14(1):81-87.
183. **Drago L**. CORR Insights®: Is Treatment With Dithiothreitol More Effective Than Sonication for the Diagnosis of Prosthetic Joint Infection? *Clin Orthop Relat Res*. 2018 Feb;476(2):439-440.
184. **Drago L**, Toscano M, Bottagisio M. Recent Evidence on Bioactive Glass Antimicrobial and Antibiofilm Activity: A Mini-Review. *Materials (Basel)*. 2018 Feb 24;11(2).
185. Bortolin M, Romanò CL, Bidossi A, Vecchi E, Mattina R, **Drago L**. BAG-S53P4 as bone graft extender and antimicrobial activity against gentamicin- and vancomycin-resistant bacteria. *Future Microbiol*. 2018 Apr;13:525-533.
186. Trentinaglia MT, Van Der Straeten C, Morelli I, Logoluso N, **Drago L**, Romanò CL. Economic Evaluation of Antibacterial Coatings on Healthcare Costs in First Year Following Total Joint Arthroplasty. *J Arthroplasty*. 2018 Jun;33(6):1656-1662.
187. Capuano N, Logoluso N, Gallazzi E, **Drago L**, Romanò CL. One-stage exchange with antibacterial hydrogel coated implants provides similar results to two-stage revision, without the coating, for the treatment of peri-prosthetic infection. *Knee Surg Sports Traumatol Arthrosc*. 2018 Nov;26(11):3362-3367.
188. Romanò CL, Trentinaglia MT, De Vecchi E, Logoluso N, George DA, Morelli I, **Drago L**. Cost-benefit analysis of antibiofilm microbiological techniques for peri-prosthetic joint infection diagnosis. *BMC Infect Dis*. 2018 Apr 2;18(1):154.
189. De Vecchi E, George DA, Romanò CL, Pregliasco FE, Mattina R, **Drago L**. Antibiotic sensitivities of coagulase-negative staphylococci and *Staphylococcus aureus* in hip and knee periprosthetic joint infections: does this differ if patients meet the International Consensus Meeting Criteria? *Infect Drug Resist*. 2018 Apr 13;11:539-546.
190. Lovati AB, Bottagisio M, Maraldi S, Violatto MB, Bortolin M, De Vecchi E, Bigini P, **Drago L**, Romanò CL. Vitamin E Phosphate Coating Stimulates Bone Deposition in Implant-related Infections in a Rat Model. *Clin Orthop Relat Res*. 2018 Jun;476(6):1324-1338.
191. Devereaux PJ, Duceppe E, Guyatt G, Tandon V, Rodseth R, Biccard BM, Xavier D, Szczeklik W, Meyhoff CS, Vincent J, Franzosi MG, Srinathan SK, Erb J, Magloire P, Neary J, Rao M, Rahate PV, Chaudhry NK, Mayosi B, de Nadal M, Iglesias PP, Berwanger O, Villar JC, Botto F, Eikelboom JW, Sessler DI, Kearon C, Pettit S, Sharma M, Connolly SJ, Bangdiwala SI, Rao-Melacini P, Hoefft A, Yusuf S;. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. *Lancet*. 2018 Jun 9;391(10137):2325-2334.
192. Shohat N, Bauer T, Buttaro M, Budhiparama N, Cashman J, Della Valle CJ, **Drago L**, Gehrke

- T, Marcelino Gomes LS, Goswami K, Hailer NP, Han SB, Higuera C, Inaba Y, Jenny JY, Kjaersgaard-Andersen P, Lee M, Llinás A, Malizos K, Mont MA, Jones RM, Parvizi J, Peel P, Rivero-Boschert S, Romano C, Segreti J, Soriano A, Sousa R, Spangehl M, Tan TL, Tikhilov R, Tuncay I, Winkler H, Witso E, Wouthuyzen-Bakker M, Young S, Zhang X, Zhou Y, Zimmerli W. Hip and Knee Section, What is the Definition of a Periprosthetic Joint Infection (PJI) of the Knee and the Hip? Can the Same Criteria be Used for Both Joints?: Proceedings of International Consensus on Orthopedic Infections. *J Arthroplasty*. 2018 Oct 22.
193. De Vecchi E, Romanò CL, De Grandi R, Cappelletti L, Villa F, **Drago L**. Alpha defensin, leukocyte esterase, C-reactive protein, and leukocyte count in synovial fluid for pre-operative diagnosis of periprosthetic infection. *Int J Immunopathol Pharmacol*. 2018 Mar-Dec;32.
194. De Grandi R, Capaccio P, Bidossi A, Bottagisio M, **Drago L**, Torretta S, Pignataro L, DeVecchi E. Salivary calculi microbiota: new insights into microbial networks and pathogens reservoir. *Microbes Infect*. 2018 Oct 29.
194. Bidossi A, De Grandi R, Toscano M, Bottagisio M, De Vecchi E, Gelardi M, **Drago L**. Probiotics *Streptococcus salivarius* 24SMB and *Streptococcus oralis* 89° interfere with biofilm formation of pathogens of the upper respiratory tract. *BMC Infect Dis*. 2018 Dec 13;18(1):653.
195. Torretta S, Guastella C, Marchisio P, Marom T, Bosis S, Ibba T, **Drago L**, Pignataro L. Sinonasal-Related Orbital Infections in Children: A Clinical and Therapeutic Overview. *J Clin Med*. 2019 Jan 16;8(1).
196. Bottagisio M, Lovati AB, Galbusera F, **Drago L**, Banfi G. A Precautionary Approach to Guide the Use of Transition Metal-Based Nanotechnology to Prevent Orthopedic Infections. *Materials (Basel)*. 2019 Jan 20;12(2).
197. **Drago L**, Pignataro L, Torretta S. Microbiological Aspects of Acute and Chronic Pediatric Rhinosinusitis. *J Clin Med*. 2019 Jan 28;8(2).
198. **Drago L**. Probiotics and Colon Cancer. *Microorganisms*. 2019 Feb 28;7(3).

Publications on Journals with Impact Factor

Total Raw Impact Factor: 501,075

Total H Index: 30

Total: citation: 3.400

Milan, march 28th, 2019

Lorenzo Drago